$NVNO

enVVeno Medical Corp

CIK:0001661053|SEC Filings

Condensed Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development expenses	$ 2,076	$ 2,891	$ 4,187	$ 5,448
Selling, general and administrative expenses	1,720	4,158	3,671	6,555
Loss from operations	(3,796)	(7,049)	(7,858)	(12,003)
Other income:
Realized gains from sales of trading securities	209	239	447	665
Unrealized loss from trading securities	(22)	(79)	(65)	(273)
Interest income	9	195	31	414
Loss from disposition of property and equipment			(4)
Total other income	196	355	409	806
Net loss	$ (3,600)	$ (6,694)	$ (7,449)	$ (11,197)
Net loss per basic common share	$ (5.37)	$ (11.52)	$ (11.18)	$ (19.27)
Net loss per diluted common share	$ (5.37)	$ (11.52)	$ (11.18)	$ (19.27)
Weighted average number of common shares outstanding:
Basic	671	581	666	581
Diluted	671	581	666	581

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Cash Flows from Operating Activities
Net loss	$ (3,600)	$ (6,694)	$ (7,449)	$ (11,197)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			864	2,095
Depreciation and amortization			(32)	74
Loss on disposition of property and equipment			4
Amortization of right-of-use assets			185	178
Unrealized loss from investments	22	79	65	273
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			18	119
Accounts payable, accrued expenses and other current liabilities			(247)	907
Operating lease liabilities			(195)	(182)
Net cash used in operating activities			(6,787)	(7,733)
Cash Flows from Investing Activities
Maturities of investments			47,253	24,835
Purchases of investments			(40,816)	(16,807)
Purchases of property and equipment				(5)
Net cash provided by investing activities			6,437	8,023
Cash Flows from Financing Activities
Proceeds from sale of common stock in At-the-Market offering, net of fees			126
Net cash provided by financing activities			126
Net (decrease) increase in cash and cash equivalents			(224)	290
Cash and cash equivalents, beginning of period			3,065	1,754
Cash and cash equivalents, end of period	$ 2,841	$ 2,044	$ 2,841	$ 2,044

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 2,841	$ 3,065
Short-term investments	18,645	25,147
Prepaid expenses and other current assets	596	614
Total current assets	22,082	28,826
Property and equipment, net	78	51
Operating lease right-of-use assets, net	469	654
Security deposits and other assets	31	31
Total assets	22,660	29,562
Current liabilities:
Accounts payable, accrued expenses and other current liabilities	1,485	1,732
Current portion of operating lease liabilities	402	390
Total current liabilities	1,887	2,122
Long-term operating lease liabilities	103	310
Total liabilities	1,990	2,432
Commitments and Contingencies – Note 7
Stockholders’ Equity:
Preferred stock, par value $0.00001, 10,000 shares authorized, no shares issued or outstanding
Common stock, par value $0.00001, 250,000 shares authorized, 673 and 656 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital	199,446	198,457
Accumulated deficit	(178,776)	(171,327)
Total stockholders’ equity	20,670	27,130
Total liabilities and stockholders’ equity	$ 22,660	$ 29,562